AUTHOR=Dan Hanyu , Jiang Qiang , Jia Xiangnan , Qi Guanpeng , Zong Dongsheng , Li Zuojing 

TITLE=Dermatologic toxicities in epidermal growth factor receptor: a comprehensive pharmacovigilance study from 2013 to 2023

JOURNAL=Frontiers in Medicine

VOLUME=Volume 10 - 2023

YEAR=2024

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1283807

DOI=10.3389/fmed.2023.1283807

ISSN=2296-858X

ABSTRACT=Despite Epidermal growth factor receptor inhibitors (EGFRIs) caused cutaneous toxicities was relatively general adverse events (AEs) that are not serious as major cancers, we still need to pay enough attention to it. Therefore, it is necessary to evaluate the diversities of EGFRIs class drugs. The objective of this study was to conduct a scientific and systematic investigation into the correlation between EGFRI and cutaneous toxicities. The data accessed from the FDA Adverse Event Reporting System database (FAERS), encompass a time frame spanning from January 2013 to the March 2023. By utilizing reporting odds ratios (RORs),information components (ICs), proportional reporting ratio (PRR) and chi-squared(χ 2 ), the relationship between drugs and adverse reactions was evaluated through disproportionality analysis. Within the FAERS database, a total of 29,559 skin adverse events were recorded. A robust indication of the correlation between EGFRI and elderly patients (≥65 years) was identified. Among EGFRIs, erlotinib accounted for the largest proportion of skin adverse events (39.72%). Rash, dry skin, and pruritus ranked top among all preferred terms, and signals such as rash, skin lesions, and acneiform dermatitis were detected in every single drug. Clinicians should guide patients customize the treatment plan for each patient.